Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
Identifieur interne : 004380 ( Main/Exploration ); précédent : 004379; suivant : 004381Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
Auteurs : Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Dyskinesia, Dyskinesia, Drug-Induced (diagnosis), Evolution, Female, Fluctuations, Follow-Up Studies, Functional Laterality (drug effects), Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Motor Activity (drug effects), Motricity, Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Treatment Outcome, dyskinesia, levodopa, motor fluctuations.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Dyskinesia, Drug-Induced, Parkinson Disease.
- drug effects : Functional Laterality, Motor Activity, Neurologic Examination.
- drug therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Thirty‐four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disease progresses. Objective measurements of the motor response to levodopa test‐doses were made at approximately three yearly intervals. Motor fluctuations developed in 58% of the patient group after a mean treatment period of 35 months. Dyskinesia developed in parallel with fluctuations but appeared on average 7 months before symptomatic wearing‐off effects of levodopa doses. The patients with motor fluctuations had significantly better responses to levodopa. By contrast, nonfluctuators were more prone to develop increasing midline motor disability affecting speech, gait and balance. Comparison of test‐dose and pretreatment scores suggested that a substantial long‐duration response to levodopa remains after many years of treatment, and that lateralized motor deficits show a stronger long duration response than midline ones. Motor fluctuations are a consequence of disease progression but their early development is, on balance, associated with better long‐term functional ability because these patients have the greater capacity to respond to pharmacological treatment. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10244
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000703
- to stream Istex, to step Curation: 000703
- to stream Istex, to step Checkpoint: 002C71
- to stream PubMed, to step Corpus: 003918
- to stream PubMed, to step Curation: 003918
- to stream PubMed, to step Checkpoint: 003A16
- to stream Ncbi, to step Merge: 000933
- to stream Ncbi, to step Curation: 000933
- to stream Ncbi, to step Checkpoint: 000933
- to stream Main, to step Merge: 006385
- to stream PascalFrancis, to step Corpus: 002596
- to stream PascalFrancis, to step Curation: 000725
- to stream PascalFrancis, to step Checkpoint: 002686
- to stream Main, to step Merge: 006725
- to stream Main, to step Curation: 004380
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease</title><author><name sortKey="Mccoll, Craig D" sort="Mccoll, Craig D" uniqKey="Mccoll C" first="Craig D." last="Mccoll">Craig D. Mccoll</name></author><author><name sortKey="Reardon, Katrina A" sort="Reardon, Katrina A" uniqKey="Reardon K" first="Katrina A." last="Reardon">Katrina A. Reardon</name></author><author><name sortKey="Shiff, Mark" sort="Shiff, Mark" uniqKey="Shiff M" first="Mark" last="Shiff">Mark Shiff</name></author><author><name sortKey="Kempster, Peter A" sort="Kempster, Peter A" uniqKey="Kempster P" first="Peter A." last="Kempster">Peter A. Kempster</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DDC993BBFA650B4222FB1422EC0A8FC16DD775C8</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10244</idno><idno type="url">https://api.istex.fr/document/DDC993BBFA650B4222FB1422EC0A8FC16DD775C8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000703</idno><idno type="wicri:Area/Istex/Curation">000703</idno><idno type="wicri:Area/Istex/Checkpoint">002C71</idno><idno type="wicri:doubleKey">0885-3185:2002:Mccoll C:motor:response:to</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12465061</idno><idno type="wicri:Area/PubMed/Corpus">003918</idno><idno type="wicri:Area/PubMed/Curation">003918</idno><idno type="wicri:Area/PubMed/Checkpoint">003A16</idno><idno type="wicri:Area/Ncbi/Merge">000933</idno><idno type="wicri:Area/Ncbi/Curation">000933</idno><idno type="wicri:Area/Ncbi/Checkpoint">000933</idno><idno type="wicri:doubleKey">0885-3185:2002:Mccoll C:motor:response:to</idno><idno type="wicri:Area/Main/Merge">006385</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0038703</idno><idno type="wicri:Area/PascalFrancis/Corpus">002596</idno><idno type="wicri:Area/PascalFrancis/Curation">000725</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002686</idno><idno type="wicri:doubleKey">0885-3185:2002:Mccoll C:motor:response:to</idno><idno type="wicri:Area/Main/Merge">006725</idno><idno type="wicri:Area/Main/Curation">004380</idno><idno type="wicri:Area/Main/Exploration">004380</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease</title><author><name sortKey="Mccoll, Craig D" sort="Mccoll, Craig D" uniqKey="Mccoll C" first="Craig D." last="Mccoll">Craig D. Mccoll</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurosciences Department, Monash Medical Centre, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author><author><name sortKey="Reardon, Katrina A" sort="Reardon, Katrina A" uniqKey="Reardon K" first="Katrina A." last="Reardon">Katrina A. Reardon</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurosciences Department, Monash Medical Centre, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author><author><name sortKey="Shiff, Mark" sort="Shiff, Mark" uniqKey="Shiff M" first="Mark" last="Shiff">Mark Shiff</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurosciences Department, Monash Medical Centre, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author><author><name sortKey="Kempster, Peter A" sort="Kempster, Peter A" uniqKey="Kempster P" first="Peter A." last="Kempster">Peter A. Kempster</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurosciences Department, Monash Medical Centre, Melbourne</wicri:regionArea><wicri:noRegion>Melbourne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1227">1227</biblScope><biblScope unit="page" to="1234">1234</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DDC993BBFA650B4222FB1422EC0A8FC16DD775C8</idno><idno type="DOI">10.1002/mds.10244</idno><idno type="ArticleID">MDS10244</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Evolution</term><term>Female</term><term>Fluctuations</term><term>Follow-Up Studies</term><term>Functional Laterality (drug effects)</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Motricity</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Treatment Outcome</term><term>dyskinesia</term><term>levodopa</term><term>motor fluctuations</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Functional Laterality</term><term>Motor Activity</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Evolution</term><term>Fluctuation</term><term>Homme</term><term>Lévodopa</term><term>Motricité</term><term>Parkinson maladie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Thirty‐four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disease progresses. Objective measurements of the motor response to levodopa test‐doses were made at approximately three yearly intervals. Motor fluctuations developed in 58% of the patient group after a mean treatment period of 35 months. Dyskinesia developed in parallel with fluctuations but appeared on average 7 months before symptomatic wearing‐off effects of levodopa doses. The patients with motor fluctuations had significantly better responses to levodopa. By contrast, nonfluctuators were more prone to develop increasing midline motor disability affecting speech, gait and balance. Comparison of test‐dose and pretreatment scores suggested that a substantial long‐duration response to levodopa remains after many years of treatment, and that lateralized motor deficits show a stronger long duration response than midline ones. Motor fluctuations are a consequence of disease progression but their early development is, on balance, associated with better long‐term functional ability because these patients have the greater capacity to respond to pharmacological treatment. © 2002 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Mccoll, Craig D" sort="Mccoll, Craig D" uniqKey="Mccoll C" first="Craig D." last="Mccoll">Craig D. Mccoll</name></noRegion><name sortKey="Kempster, Peter A" sort="Kempster, Peter A" uniqKey="Kempster P" first="Peter A." last="Kempster">Peter A. Kempster</name><name sortKey="Reardon, Katrina A" sort="Reardon, Katrina A" uniqKey="Reardon K" first="Katrina A." last="Reardon">Katrina A. Reardon</name><name sortKey="Shiff, Mark" sort="Shiff, Mark" uniqKey="Shiff M" first="Mark" last="Shiff">Mark Shiff</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004380 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004380 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DDC993BBFA650B4222FB1422EC0A8FC16DD775C8
|texte= Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |